MEOBF
Price
$1.90
Change
+$0.55 (+40.74%)
Updated
Dec 22 closing price
Capitalization
2.49B
62 days until earnings call
Intraday BUY SELL Signals
MESO
Price
$19.51
Change
+$0.11 (+0.57%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
2.49B
62 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MEOBF vs MESO

Header iconMEOBF vs MESO Comparison
Open Charts MEOBF vs MESOBanner chart's image
Mesoblast
Price$1.90
Change+$0.55 (+40.74%)
Volume$1K
Capitalization2.49B
Mesoblast
Price$19.51
Change+$0.11 (+0.57%)
Volume$604
Capitalization2.49B
MEOBF vs MESO Comparison Chart in %
MEOBF
Daily Signal:
Gain/Loss:
MESO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MEOBF vs. MESO commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEOBF is a Hold and MESO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (MEOBF: $1.90 vs. MESO: $19.40)
Brand notoriety: MEOBF and MESO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MEOBF: 45% vs. MESO: 18%
Market capitalization -- MEOBF: $2.49B vs. MESO: $2.49B
MEOBF [@Biotechnology] is valued at $2.49B. MESO’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEOBF’s FA Score shows that 0 FA rating(s) are green whileMESO’s FA Score has 0 green FA rating(s).

  • MEOBF’s FA Score: 0 green, 5 red.
  • MESO’s FA Score: 0 green, 5 red.
According to our system of comparison, MEOBF is a better buy in the long-term than MESO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEOBF’s TA Score shows that 3 TA indicator(s) are bullish while MESO’s TA Score has 6 bullish TA indicator(s).

  • MEOBF’s TA Score: 3 bullish, 3 bearish.
  • MESO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MESO is a better buy in the short-term than MEOBF.

Price Growth

MEOBF (@Biotechnology) experienced а +40.74% price change this week, while MESO (@Biotechnology) price change was +3.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.37%. For the same industry, the average monthly price growth was +0.28%, and the average quarterly price growth was +55.43%.

Reported Earning Dates

MEOBF is expected to report earnings on Feb 26, 2026.

MESO is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($2.49B) and MESO($2.49B) have the same market capitalization . MESO YTD gains are higher at: -2.020 vs. MEOBF (-13.636). MEOBF (-73.66M) and MESO (-73.66M) have comparable annual earnings (EBITDA) . MEOBF (161M) and MESO (161M) have equal amount of cash in the bank . MEOBF (128M) and MESO (128M) have identical debt. MEOBF (17.2M) and MESO (17.2M) have equivalent revenues.
MEOBFMESOMEOBF / MESO
Capitalization2.49B2.49B100%
EBITDA-73.66M-73.66M100%
Gain YTD-13.636-2.020675%
P/E RatioN/AN/A-
Revenue17.2M17.2M100%
Total Cash161M161M100%
Total Debt128M128M100%
FUNDAMENTALS RATINGS
MEOBF vs MESO: Fundamental Ratings
MEOBF
MESO
OUTLOOK RATING
1..100
5035
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
3739
P/E GROWTH RATING
1..100
5297
SEASONALITY SCORE
1..100
13n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEOBF's Valuation (84) in the null industry is in the same range as MESO (84) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's Profit vs Risk Rating (100) in the null industry is in the same range as MESO (100) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's SMR Rating (96) in the null industry is in the same range as MESO (96) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's Price Growth Rating (37) in the null industry is in the same range as MESO (39) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's P/E Growth Rating (52) in the null industry is somewhat better than the same rating for MESO (97) in the Biotechnology industry. This means that MEOBF’s stock grew somewhat faster than MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEOBFMESO
RSI
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
80%
Momentum
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
52%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
50%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
50%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
52%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
MEOBF
Daily Signal:
Gain/Loss:
MESO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HNDRX86.090.13
+0.15%
Horizon Defined Risk Investor
MOSLX8.87N/A
N/A
MassMutual Overseas Adm
GLNCX21.05-0.02
-0.09%
MFS Global New Discovery C
RIGEX44.64-0.05
-0.11%
American Funds Intl Gr and Inc R4
TGRIX13.71-0.02
-0.15%
American Century International Gr I

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
+1.29%
COGT - MEOBF
39%
Loosely correlated
-1.10%
MESO - MEOBF
26%
Poorly correlated
+1.09%
KROS - MEOBF
26%
Poorly correlated
-0.09%
More

MESO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MESO
1D Price
Change %
MESO100%
+1.09%
QTTB - MESO
51%
Loosely correlated
+2.56%
CADL - MESO
37%
Loosely correlated
+3.58%
ALGS - MESO
34%
Loosely correlated
+5.73%
TNGX - MESO
33%
Poorly correlated
+1.99%
PYPD - MESO
32%
Poorly correlated
+3.08%
More